LLY
Snapshot
mcap $1.1T · fwd P/E 26.0 · P/S 13.7 · rev +48% y/y · margin 34% · short 1.0% of float · beta 0.5 · earnings in 77d · 95% of 52w range
Active theses holding LLY
Recent news
Eli Lilly gains FDA Breakthrough nod for olomorasib in pancreatic cancer
Eli Lilly's KRAS G12C inhibitor olomorasib received FDA Breakthrough Therapy designation for advanced pancreatic cancer with a KRAS G12C mutation, adding to a prior breakthrough tag in lung cancer. Lilly also entered a c
Aug 08, 2026
CVS slashes weight-loss consultation fee to $29, targets GLP-1 market
On August 5, CVS Health cut the cash price of its MinuteClinic online weight-loss consultation to $29, the lowest in the retail telehealth market for a GLP-1 evaluation, with no membership or monthly fee. The move aims t
Aug 08, 2026
Eli Lilly joins Illumina's Billion Cell Atlas for AI drug discovery
Eli Lilly has joined Illumina's Billion Cell Atlas alliance as a foundational participant, gaining access to what is described as the world's largest genome-wide genetic perturbation dataset. The alliance is sequencing h
Jul 30, 2026
Eli Lilly's Non-GLP-1 Portfolio Growth Ahead of Q2 Earnings
Eli Lilly is set to report its Q2 2026 earnings on Aug. 5, with consensus estimates of $20.26 billion in sales and $6.71 per share, though 2026 earnings estimates have fallen from $36.59 to $34.91 per share over the past
Jul 28, 2026
Eli Lilly stock surges 53% as obesity drugs drive record revenue
Eli Lilly's stock surged 53% over the past year, driven by record revenue from its obesity and diabetes drugs, which generated $12.8 billion in Q1 2026 alone. Revenue grew 47% in the last twelve months, far outpacing the
Jul 22, 2026
Eli Lilly Stock Surges 26% After 6% EPS Guidance Raise
Eli Lilly's stock surged 26% after the company raised its 2026 EPS guidance by 5.8% to a midpoint of $36.25 on April 30, 2026, a move that quadrupled the profit forecast's percentage increase and sparked a rally more tha
Jul 20, 2026
Eli Lilly to acquire AtaiBeckley in up to $3.8B deal
Eli Lilly's acquisition of AtaiBeckley for an upfront $2.8 billion, or $6.75 per share, has driven the company's shares up more than 32% to close at $7.15, a four-year high, with trading volume surging to 164.9 million s
Jul 16, 2026
Eli Lilly Stock Could Reach $2,100 on Drug Growth
Eli Lilly's stock could reach $2,100, a 76% upside from its current $1,189, driven by revenue compounding from its drug portfolio. While Mounjaro and Zepbound contributed $6.7 billion in new quarterly growth, immunology,
Jul 15, 2026
Think you know where LLY goes next? Post the thesis and the AI scores it against live news.
Sign up free